Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Angiodynamics (ANGO) Cost of Revenue (2016 - 2026)

Angiodynamics (ANGO) has disclosed Cost of Revenue for 16 consecutive years, with $26.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue fell 18.91% year-over-year to $26.7 million, compared with a TTM value of $131.7 million through Nov 2025, down 17.76%, and an annual FY2025 reading of $134.8 million, down 9.67% over the prior year.
  • Cost of Revenue was $26.7 million for Q4 2025 at Angiodynamics, down from $33.9 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $71.0 million in Q2 2024 and bottomed at $11.5 million in Q2 2023.
  • Average Cost of Revenue over 5 years is $32.6 million, with a median of $33.0 million recorded in 2024.
  • The sharpest move saw Cost of Revenue plummeted 71.66% in 2023, then soared 517.69% in 2024.
  • Year by year, Cost of Revenue stood at $23.6 million in 2021, then grew by 10.17% to $26.0 million in 2022, then tumbled by 45.35% to $14.2 million in 2023, then surged by 131.75% to $32.9 million in 2024, then dropped by 18.91% to $26.7 million in 2025.
  • Business Quant data shows Cost of Revenue for ANGO at $26.7 million in Q4 2025, $33.9 million in Q3 2025, and $37.9 million in Q2 2025.